Vytautas Usonis is professor of Paediatrics at Vilnius University and he is currently Head of the Vilnius University Clinic of Paediatrics.

He holds undergraduate degree in medicine/paediatrics (1974). His PhD was on the immunology of viral hepatitis (1981) and his doctor habilitatus dissertation was on the immunopathogenesis and vaccine prophylactics of viral hepatitis B (1990).

Vytautas Usonis is an expert on vaccine-related issues. He is on the editorial boards of a number of national and international scientific journals as well as being a member of the international vaccination advisory and working groups.

He is (co-)author of more than 150 publications on paediatric infectious diseases published in English, Russian and Lithuanian (research articles, textbooks and chapters in textbooks on paediatric infectious diseases, vaccine preventable diseases and vaccinology, rotavirus infection, paediatric HIV infection). He has been teaching various courses on paediatric infectious diseases and vaccinology for undergraduate medical students and postgraduate physicians at Vilnius University. He supervised 10 doctorates at Vilnius University and was an external jury member of numerous doctorates and habilitations in Lithuania and abroad. He was also a tutor of Oxford University’s Postgraduate Diploma in Paediatric Infectious Diseases (2008-2015).

He is a member of the European Academy of Paediatrics (CESP) and Chair of the Board of Baltic Immunoprophylaxis Association. He has been a board member of the European Society of Paediatric Infectious Diseases (ESPID), Chair of the National Committee for Poliomyelitis Eradication Certification in Lithuania, a board member of the National Board on Immunisation of Lithuania.

He was President of the Lithuanian Paediatric Society (LPS) 2000 to 2007 retiring after two terms according to the Constitution of the Society. He has since been the Vice-President and board member. From 1997 to 2003 he was President of the UNICEF National Committee of Lithuania.

I’m a clinical microbiologist by training. As part of my doctoral degree project I assessed low-cost methods for detection of multidrug-esistant
tuberculosis. During my post-doctoral fellowship I worked with antibiotic stewardship programmes in low- and middle-income settings. Currently I work as Expert in tuberculosis in the European Centre for Disease Prevention and Control.

Winemaker, photographer and expeditionist. Also, a former MDR-TB patient. Diagnosed with MDR-TB at age 21, I finished the 2 year treatment in March 2012. I received my diagnosis and early treatment in Moldova, in Eastern Europe, but then also got treatment in USA, in California.

This experience gave me a deeper understanding how stigma and bad policy can make the worst of the TB treatment. I spend the following years being a voice for TB patients and trying to help in any way I can eradicate a disease, already curable for so many years.

Anna Turkova is a research clinician at the MRC CTU at UCL, London, and the Paediatric European Network for Treatment of AIDS (PENTA). She is an Honorary Consultant Paediatrician at Great Ormond Street Hospital, London. Prior coming to the UK in 2002, she worked for four years in Paediatric Infectious Diseases in Russia.

Anna is a member of PENTA Faculty since 2011, and has been teaching on PENTA training courses in Eastern and Western Europe, Central Asia and Africa. She is jointly leading on-line PENTA training and residential courses in Eastern Europe and Central Asia. Anna is one of the lead authors of PENTA guidelines for treatment of paediatric HIV 2015-2016.

In 2015 she was elected to the Executive Committee of the Children’s HIV Association (CHIVA), UK, and she is a current chair of the CHIVA Guidelines Subcommittee. Anna is a member of the European Society for Paediatric Infectious Diseases (ESPID) and the Paediatric Tuberculosis Network European Trials group (pTBNet). Her special interests are HIV, co-infections, viral hepatitis and TB.

Medical Education

  • Doctor of Medicine (MD), University of Antioquia Faculty of Medicine  (Medellín, Antioquia, Colombia) 01/89 – 6/94

Postdoctoral Training

  • Rotating Internship, University of Antioquia Faculty of Medicine (Medellín, Antioquia, Colombia) 07/94 – 06/95
  • Allergy & Immunology Research Fellowship, Yale University School of Medicine (New Haven, Connecticut, USA) 07/95 – 07/96
  • Combined Internal Medicine and Pediatrics Residency, New Jersey Medical School, Rutgers University (Newark, New Jersey, USA) 07/97 – 06/01
  • Combined Adult & Pediatric Infectious Diseases Clinical & Research Fellowship, University of Colorado School of Medicine (Denver, Colorado, USA) 07/03 – 06/07
  • Clinical Tropical Medicine Diploma Course (DTM&H), Gorgas Memorial Institute of Tropical & Preventive Medicine of the University of Alabama at Birmingham, and Alexander von Humboldt Institute of Tropical Medicine of the Cayetano Heredia University (Lima, Peru) 02/04 – 04/04

Clinical Work Experience (relevant to TB)

  • Attending Physician, Tuberculosis Clinic, Pima County Health Department (Tucson, Arizona, USA) 02/16 – Present
  • Attending Physician, Denver Metro Tuberculosis Clinic, Denver Health Medical Center (Denver, Colorado, USA) 11/07 – 10/10
  • Attending Physician, Adult & Pediatric Respiratory & Mycobacterial Infections Service, National Jewish Hospital (Denver, Colorado, USA) 07/07 – 10/10
  • Technical Assistant, Tuberculosis Control Program, Public Health Department, Valle del Cauca (Cali, Valle del Cauca, Colombia) 07/06 – 06/07

Academic Work Experience

  • Division of Infectious Diseases, University of Arizona College of Medicine–Tucson (Tucson, Arizona, USA) 02/16 – Present
  • Division of Infectious Diseases, University of Arizona College of Medicine–Phoenix (Phoenix, Arizona, USA) 09/13 – 12/15
  • Division of Infectious Diseases, University of Antioquia Faculty of Medicine (Medellin, Antioquia, Colombia) 01/11 – 02/13

Division of Infectious Diseases, University of Colorado School of Medicine (Denver, Colorado, USA) 07/07 – 10/10

Doctor Mariandyshev Andrei is the head and professor of the department of Phthisiopulmonology of the Northern State Medical University in Arkhangelsk. He is the main TB specialist of the regional Ministry of Public Health in the Arkhangelsk region and North–West Federal Okrug of the Russian Federation. DOTS and DOTS+ TB programmes were successfully implemented in the Arkhangelsk region. Since 2002 the International Federation of Red Cross and Red Crescent Societies has invited him as a main consulter of the implementation of the DOTS and DOTS+ programs in ten administrative subdivisions of the Russian Federation. He was invited as an international expert for the evaluation programmatic management drug resistant TB programs in nine countries. Since 2011 he is a chair Green Light Committee Europe region WHO.  He has published more forty scientific articles in the international journals.

MRC Clinical Trials Unit at University College London

Academic degrees

1977 MBChB Distinctions in Medicine, Paediatrics, Pathology (Subtle Gold medal for medicine) Bristol University

1979 Diploma Obstetrics and Gynaecology Auckland, New Zealand

1982 FRACP Paediatrics (Part 1) Royal Australian College Australia

1985 MRCP Paediatrics Royal College of Physicians, UK

1988 MD Markers of Renal Complications in Diabetic Children Bristol University

1990 MSc Epidemiology London School of Hygiene and Tropical Medicine

Diana is professor of Epidemiology and Programme Leader of the Paediatric Programme of trials and cohorts at the MRC Clinical Trials Unit at UCL. Over the last 28 years she has set up and coordinated a network of clinical trials and cohorts, across Europe, Thailand and South America mainly addressing questions in paediatric HIV infection.  Since 2000 focus has expanded to Africa where she runs large trials, addressing strategy questions in adult and paediatric HIV infection, tuberculosis and malaria, collaborating widely with clinical and research centres in 6 countries in East and Southern Africa.  These include the ongoing SHINE (Shorter treatment for minimal TB in children) and TB CHAMP trial (TB child multidrug-resistant preventive therapy). She serves on a number of WHO advisory and guideline committees and continues a clinical commitment at the HIV Family clinic at the Great Ormond Street Hospital for Children in London, which she started in 1991.

Claudio is a visiting scientist at the University of Cambridge, as well as a consultant for the Foundation for Innovative New Diagnostics (FIND) and several diagnostics companies. He is a member of the World Health Organization Task Force on PK/PD of tuberculosis medicines. His main interests lie in elucidating the genetic basis of antibiotic resistance in the Mycobacterium tuberculosis complex and in translating next-generation sequencing as a diagnostic tool.

Dr Dravniece is a senior Tuberculosis expert combining extensive clinical experience with outstanding pro-gramme management skills. Following a successful career in clinical care of tuberculosis (TB) and   multi-drug resistant TB (MDR-TB) she joined the KNCV Tuberculosis Foundation providing expertise in MDR-TB programme management.

Consultant Clinical Microbiologist and Director of National Reference Mycobacteriology Services (NMRS), National Infection Service from 2015

Director of the PHE National Mycobacteriology Reference Service Central and North,    Birmingham Public Health Laboratory from 1995

Responsible for a national reference service from Reference Laboratories in Birmingham and London to NHS laboratories, clinicians and Public Health colleagues in England, delivering high quality reference tests to identify isolates of TB and other mycobacteria, antibiotic susceptibilities and transmission clusters by genomic analysis. I provide a service advising on management and infection control of complex cases of TB and infections with other mycobacteria, working with clinical and Public Health colleagues and am a Clinical Service Advisor on the British Thoracic Society MDRTB Clinical Advice Service and a member of the PHE National TB Programme Board and TB Strategy  Delivery Groups, as well as the TB Control Board for the West Midlands and the  Birmingham, Solihull and Sandwell TB Board.

In 2014 I was appointed by PHE to pilot TB whole genome sequencing into an accredited service for national deployment; to provide TB results for the NHS in 5 days which currently take 6 to 8 weeks for identification, drug resistance and transmission of TB. This was introduced into clinical service for North and Central England in December 2016 as a world first, and the service will be introduced to the rest of England in January 2018.

I have worked closely with colleagues at Oxford University since 2009 and am co-applicant on a number of grants for work on translation of whole genome sequencing into improved diagnosis and care for patients with mycobacterial infections

Visiting Professor on Respiratory Infections to the National Heart and Lung Institute at Imperial College, London from December 2014, and Deputy Director of the NIHR funded HPRU in Respiratory Infection at Imperial College

I am a retired Consultant in Infectious Diseases and Respiratory Medicine who worked at Heartlands Hospital in Birmingham, England.  I graduated in medicine from Edinburgh University Medical School in 1970 and took up my post in Birmingham in 1978 at a time when tuberculosis in immigrant families from South Asia was increasingly prevalent.

My main professional interests have been in the field of tuberculosis, including clinical diagnosis and management, Public Health measures and postgraduate training.  I have published research on a number of topics in tuberculosis including the use of interferon-gamma release assays and molecular epidemiology.  Between 1999 and 2017 I held a biannual national training course in Tuberculosis Management and Control for doctors, nurses and medical scientists.  I was a member of the Guideline Development Group for the first UK NICE Guidelines on TB published in 2006.

Helen Fletcher is an Associate Professor of Immunology and Deputy Director of the TB Centre at the London School of Hygiene & Tropical Medicine (LSHTM). Helen’s research interests include tuberculosis (TB) vaccine development and identification of immune mechanisms important for protection from TB. Since 2000 She has worked with scientists across Africa in The Gambia, Zambia, Ethiopia, Senegal, Kenya, South Africa and Uganda. Helen is a research group leader at LSHTM where she continues her research in TB vaccines and immune correlates of risk. Helen is also co-investigator of The VALIDATE Network https://www.validate-network.org/.  An MRC funded Network of UK and LMIC scientists working to develop vaccines for TB, melioidosis, leishmaniasis and leprosy. Helen has a PhD in Microbiology from the University of Leeds where she also completed her undergraduate degree. She is co-Editor of the journal Tropical Medicine and International Health (TMIH) and has written over 100 peer review research articles and chapters.

Following her MBChB at UCT, Prof McIlleron worked as a clinician before taking up a research position in the Division of Clinical Pharmacology, UCT where she completed her PhD on the pharmacokinetics (PK) and pharmacodynamics (PD) of tuberculosis (TB) drugs in patients with drug susceptible disease. Since then she has lead and collaborated on multiple PK and PK/PD studies of anti-TB drugs and antiretrovirals in adults and children with focus on TB/HIV co-infection and special populations. She strongly believes in the development of investigator-driven research for these diseases with the application of analytical tools facilitating research to optimize treatment in the relevant populations.

Suzanne Anderson – mini biog March 2018

Suzanne is a paediatrician with a long standing interest in tropical child health and childhood tuberculosis. After completing a PhD on TB genetics with Imperial College and the University of Cape Town, she trained in London as a community paediatrician with an interest in infectious diseases, the health of vulnerable children, refugees and immigrant health.

From 2007 to 2016 she was working in sub-Saharan Africa, initially running a TB diagnostics project at the Malawi-Liverpool-Wellcome Clinical Programme and then, for five years, was head of clinical services at the MRC Unit Gambia. She is now working in community child health in London.

James Seddon is a Clinical Senior Lecturer at Imperial College London and Honorary Consultant in Paediatric Infectious Diseases at St Mary’s Hospital, London. His major area of research is that of children with tuberculosis, specifically drug-resistant forms and he divides his time between London and Cape Town. He is currently funded through an MRC Clinician Scientist Fellowship to evaluate correlates of risk in children exposed to multidrug-resistant tuberculosis.

Joe is a social worker with nearly 20 years’ experience in the fields of child protection, mental ill-health and substance dependence. Since 2007, he has been with the pan-London TB outreach team, Find&Treat. Joe is dedicated to helping end health inequalities. He has been a member of several NICE guideline development groups and was part of the team that went to New York to bring Cohort Review to the UK. He has been involved in a number of TB research initiatives. Most recently being a researcher with the team at University College London conducting the world’s first Video Observed Treatment (VOT) randomised controlled trial. He is currently lead for the Find&Treat VOT service.

Steve Welch is education and training lead for pTBnet and for PENTA (Paediatric European Network for the Treatment of AIDS). He trained in medicine in Oxford and London, and in paediatrics and infectious diseases in London. He has been consultant in paediatric HIV and infectious diseases in Birmingham, UK since 2006, and is clinical lead for paediatric TB in Birmingham & Solihull. He is a committed European, born in Belgium and raised in Germany and the Netherlands. He enjoys walking his dog and living quietly.